The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]
This article is a run-through of organoids and organs-on-chips in drug discovery! Drug discovery has a […]
Radioligand therapy is now a board-level topic in Japan, not because the science is new, but […]
A New Order is taking shape in Japan’s life sciences. Conference floors are packed, university benches […]
In the mid-1990s, Japan was not merely participating in the global pharmaceutical industry—it was shaping it. […]
Japan’s IVD sector remains highly structured and closely governed, benefiting from a mature healthcare infrastructure and […]
Japan is the fourth-largest global medical device market, with its healthcare system actively integrating digital tools […]
Some of Japan’s most forward-thinking minds gathered to scrutinise Japan’s biobank conundrum at Shonan iPark. In […]